Stem Cell Transplant and Zoledronic Acid Improve Outcome in Previously Untreated Patients With Multiple Myeloma

Results of Phase III Study to Assess if Zoledronic Acid Have Antumor Activity in Multiple Myeloma

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01234129

Enrollment

320

Registered

2010-11-04

Start date

2002-06-30

Completion date

2009-12-31

Last updated

2010-11-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Myeloma

Keywords

multiple myeloma, stem cell transplant, zoledronic acid

Brief summary

Assess the impact in outcome of the use of zoledronic acid in multiple myeloma.

Detailed description

Assess if the use of zoledronic acid can improve outcome in patients with multiple myeloma whose are treated with cytoreductive therapy and stem cell transplant.

Interventions

DRUGzoledronic acid

zoledronic acid, 4 mg,standard dose,at monthly interval, by 2 years

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

Diagnosis of multiple myeloma No previous treatment Symptomatic High risk (ISS) or stage III ( Durie-Salmon) No severe comorbidities -

Exclusion criteria

Pregnancy HIV + Refuse treatment \-

Design outcomes

Primary

Measure	Time frame	Description
progression-free disease and overall toxicity in myeloma multiple	3 years	In patients treated with cytoreductive therapy following by stem cell transplant and that received zoledronic acid by 2 years,they were evaluable for assess antitumor effect of zoledronic acid

Secondary

Measure	Time frame	Description
skeletal event	3 years	evaluate the number of skeletal events in patients with multiple myeloma that received zoledronic acid

Countries

Mexico

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026